Scholarlink

<p>The increasing prevalence of chronic pain and inflammation has led to the exploration of alternative therapies, with electroceuticals emerging as a promising solution. Electroceuticals utilize electrical impulses to modulate neural circuits and inflammatory pathways, providing a non-pharmacological approach to treating these conditions. The integration of nanomaterials into electroceutical devices has further enhanced their effectiveness, enabling more precise, localized, and energy-efficient stimulation. Nanomaterials such as graphene, carbon nanotubes, conductive polymers, and metal-based nanoparticles are particularly suited for these applications due to their exceptional electrical properties, biocompatibility, and ability to be fine-tuned for specific biomedical purposes. Recent advancements have led to the development of personalized electroceutical therapies that leverage artificial intelligence (AI) and adaptive systems to optimize treatment based on real-time physiological data. Additionally, several patented electroceutical technologies, including vagus nerve stimulation (VNS), spinal cord stimulation (SCS), and deep brain stimulation (DBS), have demonstrated clinical promise in reducing pain and inflammation. However, the environmental impact of nanomaterial-derived electroceuticals is an emerging concern that requires attention. The production, usage, and disposal of nanomaterials pose potential risks, including toxicity to ecosystems, bioaccumulation, and challenges in waste management. This review examines the role of nanomaterial-derived electroceuticals in personalized pain and inflammation management, highlighting key technologies, patents, environmental concerns, and their potential for future clinical applications. Despite challenges in material biocompatibility, device stability, regulatory approval, and environmental sustainability, electroceuticals represent a transformative approach to personalized healthcare, offering targeted, non-invasive solutions for chronic pain and inflammatory diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanomaterial derived electroceuticals for personalized pain and inflammation: technologies and patents

  • 期刊论文

  • 发表日期：

    2025年4月25日

查看全文
  • Dilpreet Singh,
  • Akshay Thakur,
  • Kuldeep Singh

摘要

The increasing prevalence of chronic pain and inflammation has led to the exploration of alternative therapies, with electroceuticals emerging as a promising solution. Electroceuticals utilize electrical impulses to modulate neural circuits and inflammatory pathways, providing a non-pharmacological approach to treating these conditions. The integration of nanomaterials into electroceutical devices has further enhanced their effectiveness, enabling more precise, localized, and energy-efficient stimulation. Nanomaterials such as graphene, carbon nanotubes, conductive polymers, and metal-based nanoparticles are particularly suited for these applications due to their exceptional electrical properties, biocompatibility, and ability to be fine-tuned for specific biomedical purposes. Recent advancements have led to the development of personalized electroceutical therapies that leverage artificial intelligence (AI) and adaptive systems to optimize treatment based on real-time physiological data. Additionally, several patented electroceutical technologies, including vagus nerve stimulation (VNS), spinal cord stimulation (SCS), and deep brain stimulation (DBS), have demonstrated clinical promise in reducing pain and inflammation. However, the environmental impact of nanomaterial-derived electroceuticals is an emerging concern that requires attention. The production, usage, and disposal of nanomaterials pose potential risks, including toxicity to ecosystems, bioaccumulation, and challenges in waste management. This review examines the role of nanomaterial-derived electroceuticals in personalized pain and inflammation management, highlighting key technologies, patents, environmental concerns, and their potential for future clinical applications. Despite challenges in material biocompatibility, device stability, regulatory approval, and environmental sustainability, electroceuticals represent a transformative approach to personalized healthcare, offering targeted, non-invasive solutions for chronic pain and inflammatory diseases.